Biopharmaceutical company Aelis Farma (Euronext: AELIS) announced on Monday that it has received a second positive recommendation from the Independent Data Monitoring Committee (IDMC) following its review of the Phase 2b trial of AEF0217 in people with Down syndrome. The committee identified no safety concerns and recommended that the study continue without protocol modifications, while also supporting the potential initiation of a 12-month open-label extension.
The review covered safety data from 74 participants, including 54 who had completed at least 12 weeks of treatment. Of 42 treatment-emergent adverse events reported by 23 participants, 97.6% were mild. No serious or severe adverse events, treatment discontinuations or withdrawals due to adverse events were recorded. The findings also showed no clinically significant laboratory, cardiovascular or other safety signals.
The positive assessment extends to older adolescents aged 16-17, with adverse event rates comparable to those in adults, further supporting AEF0217's safety and tolerability profile.
The Phase 2b trial is progressing, with 108 of the planned 188 participants randomised as of 4 November 2026. Thirty-eight participants have completed the 24-week treatment period, with results expected by the end of 2027.
AEF0217 is a first-in-class candidate targeting cognitive impairments associated with Down syndrome and belongs to Aelis Farma's proprietary CB1 signalling-specific inhibitor (CB1-SSi) class.
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Medivir secures US patent protection for fostrox and lenvatinib combination until 2044
PharmaLogic to acquire CDMO business and manufacturing facility from Lantheus
Ribo submits European Clinical Trial Application for SR122 in mixed and severe dyslipidaemia
Spermosens and Genea agree IVF study of JUNO-Checked in Australia